Rate of complete metabolic responses to immune checkpoint inhibitors in extremely heavily pre-treated patients with classical Hodgkin’s lymphoma and immunoepigenetic priming.
2016
e19012Background: Options for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after failure of brentuximab vedotin (Bv) and ASCT are limited. cHL is associated with genetically determine...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
5
Citations
NaN
KQI